ArticleMedicine2026
Progesterone resistance in atypical endometrial hyperplasia: Expression and mechanisms of hormone-responsive molecules.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to delineate the molecular profile underlying progesterone resistance in atypical endometrial hyperplasia (AEH), a precancerous condition associated with a high risk of malignant transformation. Using a retrospective cohort of 20 AEH patients who completed a 6-month progestin therapy, we compared protein expression between 10 progesterone-resistant and 10 progesterone-sensitive tissues using immunohistochemistry and Western blot analysis. The results revealed a distinct molecular signature in resistant tissues, characterized by significant upregulation of estrogen signaling components (ERa, pS2, and MUC1) and proliferation markers (SOX7 and Ki-67). Concurrently, the key progesterone receptor signaling elements (PR, FKBP4, FKBP5, and FOSL2) were markedly downregulated. These findings indicate that progesterone resistance is associated with sustained activation of estrogen-driven proliferative pathways coupled with impaired progesterone signaling, leading to unabated cellular growth. The coordinated dysregulation of these hormone-responsive and proliferation-related molecules highlights a fundamental hormonal imbalance and proliferative disruption in progesterone-resistant AEH. This study provides a molecular framework for understanding progesterone resistance and suggests potential targets, such as SOX7, for future therapeutic strategies aimed at restoring hormonal sensitivity and controlling disease progression in conservative fertility-sparing management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.